SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention amid volatile natural-gas futures, with traders weighing winter weather forecasts, storage reports and pipeline or LNG supply disruptions. Bulls see potential for weather-driven demand and supply tightness, while bears point to mild-weather expectations, ample production and the leveraged funds compounding and futures-roll risks.

ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is drawing attention as traders bet on weaker natural-gas prices, pointing to large storage injections, ample production, and expectations of mild weather or a warm winter. Others see potential support from heat-driven demand, LNG or pipeline disruptions, and tighter storage, leaving the discussion focused on volatile swings and the risks of holding a leveraged ETF.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline: FDA clearance to expand its recurrent glioblastoma trial and upcoming GBM data, alongside completion of enrollment in its pancreatic cancer study. Traders are broadly bullish on the approaching clinical milestones, while some point to price consolidation and note that early results still need validation in larger cohorts.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Reports that the U.S. would not strike Iran have fueled hopes for a relief bounce, but traders remain divided over whether the conflict and elevated oil prices still threaten markets. Attention is also on a packed week of Fed decisions, major tech earnings, and GDP and inflation data, adding to expectations for volatility.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention as traders watch upcoming earnings and its role supplying indium-phosphide substrates for AI data-center optics. Bulls point to AI-driven demand and growth potential, while bears focus on the stocks sharp volatility, rich valuation, and China-related supply risks.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

EWZ is drawing attention around Brazils presidential runoff, with traders positioning for a possible Flvio Bolsonaro win that they view as more market-friendly. Optimistic call activity and the ETFs sharp run-up are countered by downside hedges and concerns that the result may already be priced in, keeping the focus on election-driven volatility.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys run toward record highs and anticipation of its quarterly report are driving attention, with traders expecting continued Mounjaro and Zepbound demand to support results and guidance. The outlook is broadly bullish, though some traders question the stocks valuation and flag intensifying competition in oral obesity drugs.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention after crude surged on fears of renewed US-Iran conflict and possible disruptions to Gulf oil flows. Traders are split between viewing the rally as a sustained supply-risk premium and expecting de-escalation or a pullback after the sharp run-up.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Positive prostate-cancer trial updates, including data on J&Js investigational JNJ-6143 and apalutamide, are driving attention. Traders are broadly optimistic about the oncology news, while debating whether it can sustain a share-price recovery or is already reflected in the stock.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios sharp selloff is being discussed as part of broader pressure on tech and growth stocks after a strong rally, with traders speculating that profit-taking and fading S&P 500 inclusion-related buying added to the decline; no new company-specific catalyst is established. Reactions are split between bearish traders pointing to technical weakness and buyers looking for a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INSM Stock Slides on CFO Exit, Reiterates '26 Sales View

Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal

Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work

NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.

Novo's Wegovy Pill Shows Weight Loss After Switching From Injections

NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.

Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.

NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk

Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eliseev on February 13, 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA

ACIU Stock Heads For Best Day In Over 10 Months On FDA Fast Track Nod For Parkinson’s Disease Therapy – Retail Sees ‘Breakout Soon’

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The FDA also cleared the company’s Investigational New Drug application.</li><li>The full 100-week results from the first part of the trial are expected in the second half of 2026.</li><li>AC Immune has total cash resources of $92.9 million, which it expects to fund operations into the fourth quarter of 2027.</li></ul>Shares of AC Immune (ACIU) surged more than 16% on Tuesday, after the U.S. Food and Drug Administration granted Fast Track designation to its experimental immunotherapy for early-stage Parkinson’s disease.<a href="https://stocktwits.com/symbol/ACIU">ACIU shares</a> are on track to clock their biggest intraday gains since October 2025.<h2 class="st-heading-2">FDA Clears Investigational New Drug Application</h2>Fast Track designation is intended for treatments targeting serious diseases with unmet medical needs. It allows AC Immune to communicate with the FDA more frequently during the trials. AC Immune’s ACI-7104 could also become eligible for accelerated approval or priority review if it meets the relevant requirements.However, the designation does not mean that the treatment has been approved or that its effectiveness has been established.The FDA also cleared the company’s Investigational New Drug (IND) application, allowing the ongoing Phase 2 VacSYn study to expand to clinical sites in the U.S.<h2 class="st-heading-2">Full Results Expected In Second Half Of 2026</h2>ACI-7104 is designed to generate antibodies that target toxic, aggregated forms of a protein called alpha-synuclein. The buildup of this protein is linked to inflammation and the loss of brain cells associated with Parkinson’s disease.Interim results from the trial showed that the therapy was generally safe and well tolerated through 76 weeks, with no clinically significant safety concerns. All treated patients produced the targeted immune response, giving the study a 100% responder rate.The full 100-week results from the first part of the trial are expected in the second half of 2026. According to AC Immune’s quarterly statements last week, the firm has total cash resources of CHF75.4 million ($92.9 million), which it expects to fund operations into the fourth quarter of 2027.<h2 class="st-heading-2">ACIU Bulls Eye Breakout</h2>Retail sentiment surrounding ACIU on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes.One user said the fast-track designation could lead to the stock breaking out “soon.”<stembedurl>https://stocktwits.com/BLD33/message/661530497</stembedurl>ACIU shares have declined more than 25% so far in 2026.(Exchange Rate: CHF1 = $1.23)Also read: <a href="https://stocktwits.com/news-articles/markets/equity/citi-says-hims-and-hers-full-year-outlook-indicates-hefty-q4-earnings-lift-warns-of-execution-risks/cZoNbc5RJQC">Citi Says Hims &amp; Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CHINA - 2025/10/02: In this photo illustration, the AC Immune logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The U.S. Food and Drug Administration granted Fast Track designation to AC Immune’s experimental immunotherapy ACI-7104 for early-stage Parkinson’s disease.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.42
Prev Close	$2.50
Open	$2.46
Dividend Yield	0.00%
50-Day Moving Average	$2.64
Beta	1.00
Avg. Volume	166,054.53
PE Ratio	-4.35

52-Week High	$4.00
52-Week Low	$2.10
Market Capitalization	$246.29M
EPS (Annual)	-$0.8419
Price to Book	5.06
Revenue Per Employee	$35,264.75

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACIU Fundamentals